Lilly’s oral lipid drug passes mid-stage testnews2024-11-19T15:56:21+00:00November 19th, 2024|Endpoints News|
J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that’s expected to be a blockbusternews2024-11-19T15:54:03+00:00November 19th, 2024|Endpoints News|
#ACR24: Bristol Myers takes on autoimmune diseases with cell therapy; New data from Cabaletta and Kyvernanews2024-11-19T15:52:02+00:00November 19th, 2024|Endpoints News|
Bayer, Cytokinetics make a deal in Japan; Ex-Carmot CEO to run LB Pharmaceuticalsnews2024-11-19T15:07:28+00:00November 19th, 2024|Endpoints News|
Pharma telehealth programs are catching on and raising questionsnews2024-11-19T14:30:46+00:00November 19th, 2024|Endpoints News|
Pharma’s global access efforts have stalled, new report findsnews2024-11-19T13:00:59+00:00November 19th, 2024|Endpoints News|
Jupiter Bioventures raises $70M fund for ‘super-early’ sciencenews2024-11-19T13:00:15+00:00November 19th, 2024|Endpoints News|
Merck finally has subcutaneous Keytruda results, and it’s going to regulatorsnews2024-11-19T12:28:39+00:00November 19th, 2024|Endpoints News|
Incyte ends enrollment in Phase 2 chronic hives trial due to preclinical safety concernsnews2024-11-19T12:18:59+00:00November 19th, 2024|Endpoints News|
Synapticure raises $25M for neurodegenerative disease approachnews2024-11-19T12:00:22+00:00November 19th, 2024|Endpoints News|
